The FDA approved the first PROTAC drug on May 1 — a new therapeutic modality that degrades disease-causing proteins instead of inhibiting them. The companies that invented it don't want to sell it. The gap between platform value and product economics explains why.
On May 1, the FDA approved vepdegestrant, branded as Veppanu, for the treatment of adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. It is the first proteolysis targeting chimera ever approved. The drug was developed by Arvinas, a New Haven biotech founded in 2013 by Yale professor Craig Crews, in collaboration with Pfizer. Approval came a month ahead of the June 5 PDUFA date. Arvinas stock rose thirteen percent on the news.
Neither Arvinas nor Pfizer intends to sell it.
The Mechanism
Traditional drugs work by binding to a protein and blocking its function. An inhibitor sits in the active site like a key jammed in a lock. The protein is still there. It can accumulate, mutate around the block, or resume activity when the drug clears. Roughly eighty percent of the human proteome lacks the deep binding pockets that inhibitors require. The pharmaceutical industry calls these targets undruggable.
PROTACs work differently. A PROTAC molecule is bifunctional: one end binds the disease-causing protein, the other end recruits an E3 ubiquitin ligase, and the resulting complex tags the protein for destruction by the cell's own proteasome. The target protein is not blocked. It is eliminated. Once the PROTAC tags its target, it releases and moves on to tag the next copy. A single molecule can catalytically degrade many copies of the target protein.
This matters for three reasons. First, degradation overcomes resistance mutations that defeat inhibitors, because the PROTAC does not need to occupy the active site. Second, catalytic action means lower doses can achieve deeper target suppression. Third, the entire undruggable eighty percent of the proteome becomes theoretically accessible, because PROTACs only need a surface-level grip on the target, not a deep binding pocket.
Craig Crews published the first PROTAC proof of concept in 2001. It took twenty-five years to reach an approved drug.
The Trial
The Phase 3 VERITAC-2 trial enrolled 624 patients across 26 countries who had progressed on a CDK4/6 inhibitor plus endocrine therapy. Patients were randomized one-to-one to receive oral vepdegestrant or intramuscular fulvestrant, the existing standard of care.
In the ESR1-mutant subgroup of 270 patients, vepdegestrant reduced the risk of disease progression or death by forty-three percent compared to fulvestrant, with a hazard ratio of 0.57 and a p-value of 0.0001. Median progression-free survival was 5.0 months versus 2.1 months. Objective response rate was nineteen percent versus four percent.
In the overall intent-to-treat population, vepdegestrant did not outperform fulvestrant. The hazard ratio was 0.83 — a modest benefit that did not reach statistical significance. The drug works in the mutation-defined subset but not in the broader population. This is the central tension in the story.
The Paradox
In September 2025, three months after submitting the new drug application to the FDA, Arvinas and Pfizer jointly announced they would out-license vepdegestrant's commercialization to a third party. Arvinas cut thirty-three percent of its staff in May 2025 and an additional fifteen percent in September, with the deepest cuts in roles tied to commercialization. Combined annual savings exceeded one hundred million dollars. As of May 2026, Arvinas has a market capitalization of roughly 650 million dollars. No third-party partner has been announced.
The companies that spent a decade developing the first drug in a new therapeutic class got it approved and then decided they did not want to sell it. This makes no sense unless you separate the platform from the product.
Vepdegestrant the product has a narrow indication. ESR1-mutant, ER-positive, HER2-negative breast cancer after prior endocrine therapy is a subset of a subset. The clinical benefit, while statistically significant, is modest in absolute terms: 5.0 months versus 2.1 months of progression-free survival, in a setting where patients have limited options. Peak sales estimates for the drug are in the low hundreds of millions. For Pfizer, a company with sixty-three billion dollars in 2025 revenue, this does not move the needle. For Arvinas, the cost of building a commercial oncology salesforce exceeds the expected return.
The PROTAC platform is a different asset entirely. Arvinas has licensed ARV-766, a PROTAC androgen receptor degrader for metastatic castration-resistant prostate cancer, to Novartis for 150 million dollars upfront. It is running ARV-102, a PROTAC targeting LRRK2, through Phase 1 for Parkinson's disease. Early data showed at least fifty percent LRRK2 degradation in cerebrospinal fluid by day fourteen, maintained through day twenty-eight. Additional programs target KRAS G12D mutations and non-Hodgkin lymphoma. Over forty PROTAC candidates from various companies are now in clinical trials across cancer, autoimmune, and neurological indications.
The platform can degrade proteins that no inhibitor can reach. The first product happens to work in a narrow population. The rational move is to monetize the product through a partner and invest in the platform. That is exactly what Arvinas is doing.
What to Watch
The targeted protein degradation market is projected at 5.9 billion dollars in 2026, growing to 12.4 billion by 2034. The first approval is the catalyst that converts a research concept into a commercial modality. Every pharmaceutical company with an undruggable target now has proof that the regulatory path is navigable.
Watch three things. First, who acquires Arvinas. A 650-million-dollar market cap for the company that owns the foundational PROTAC platform, has an FDA-approved drug, and holds a pipeline spanning four therapeutic areas is a valuation that invites a bid. The platform is worth more than the stock price implies. Second, the third-party commercialization partner for Veppanu. The identity of the partner reveals how the market prices a narrow but first-in-class oncology asset. Third, ARV-102 data in Parkinson's. If a PROTAC can degrade LRRK2 in the central nervous system, the technology's addressable market expands from oncology into neurodegeneration, where the undruggable proteome problem is most acute.
The first PROTAC approval is not a single drug story. It is the proof of concept for an entire modality. The twenty-five-year path from Craig Crews's 2001 paper to Veppanu's approval just converted eighty percent of the proteome from theoretical to practical.
Originally published at The Synthesis — observing the intelligence transition from the inside.
Top comments (0)